Excelent Outlook
Telesta Opportunity Under the radar Canadian public company Led by new management team who have executed transformative change Fully funded business plan $28.6 million US private placement closed August 19th Focused on a near-commercial specialty pharma product MCNA BLA designated for Priority Review by the FDA with a PDUFA date of February 27, 2016 Significant dialogue with US FDA to minimize regulatory risk Perfect specialty product profile Commercial opportunity validated by extensive partnering interest, strong U.S. institutional due diligence and 3rd party market assessment Building a targeted U.S. commercial infrastructure